Safety and efficacy of glucocorticoids in the treatment of COVID-19: A meta-analysis of randomized control trials.

Glucocorticoids (especially dexamethasone) reduce mortality of patients with severe and critical COVID-19 with no significant effect on the incidence of adverse reactions (moderate quality). In contrast, glucocorticoids do not benefit patients with mild symptoms (low quality).